|
Neonatal Intensive Care Drug Manual
|
| bet | 96/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Adverse reactions
|
Nephrolithiasis with long term use.
Gastric irritation, diarrhoea and NEC have occurred during oral therapy with hyperosmolar preparations (must dilute with water)
|
Compatibility
|
|
Incompatibility
|
Do not mix with any medication that contains phosphates, carbonates, sulfates or tartrates.
|
Stability
|
Oral solution: Discard remaining after use.
Calcium gluconate is a supersaturated solution and may precipitate in the vial at room temperature. Inspect the vial before use.
|
Storage
|
Caltrate 600mg tablets: Store below 25°C.
Cal-600 tablets: Store below 25°C.
AUSPMAN suspension: Store below 25°C.
Calcium Gluconate Injection (Phebra) : Store below 30°C. Do not refrigerate.
Calcium Chloride Injection (Phebra): Store below 25°C.
|
Excipients
|
Caltrate tablets: Excipients not listed.
Cal-600 tablets: Excipients not listed.
AUSPMAN suspension: Hydroxybenzoate.
Calcium Gluconate Injection (Phebra) (calcium 0.22 mmol/mL): Excipients not listed..
Calcium Chloride Injection (Phebra) 10%: Sodium hydroxide and/or hydrochloric acid may be used for pH adjustment.
|
|
|
| |
